28/04/2025Published by Fondazione Gianni Bonadonna at 28/04/2025Categories Events UncategorizedAvelumab plus axitinib versus sunitinib as first-line treatment in advanced renal cell carcinoma
14/04/2025Published by Fondazione Gianni Bonadonna at 14/04/2025Categories Events UncategorizedDNA methylation landscape of primary triple-negative breast cancer
07/04/2025Published by Fondazione Gianni Bonadonna at 07/04/2025Categories Events UncategorizedThe validation of the ORACLE biomarker in lung adenocarcinoma
31/03/2025Published by Fondazione Gianni Bonadonna at 31/03/2025Categories Events UncategorizedIvonescimab versus pembrolizumab in PD-L1-positive non-small cell lung cancer
24/03/2025Published by Fondazione Gianni Bonadonna at 24/03/2025Categories Events UncategorizedTiragolumab with atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
17/03/2025Published by Fondazione Gianni Bonadonna at 17/03/2025Categories Events UncategorizedIbrutinib plus venetoclax in refractory mantle cell lymphoma
10/03/2025Published by Fondazione Gianni Bonadonna at 10/03/2025Categories Events UncategorizedNew insights into the drivers and dynamics of HER2+/ER+ breast cancer response to targeted treatments
03/03/2025Published by Fondazione Gianni Bonadonna at 03/03/2025Categories Events UncategorizedNivolumab and ipilimumab in metastatic colorectal cancer
24/02/2025Published by Fondazione Gianni Bonadonna at 24/02/2025Categories Events UncategorizedEncorafenib, cetuximab and chemotherapy in metastatic colorectal cancer
